

# Baby Oncologists Unveil SERENA-6 Breast Cancer Breakthroughs

Transcript of Video Narration  
Recorded on August 19, 2025  
All Rights Reserved 2025

## Narration

- Are we really treating breast cancer the right way?
  - By the end of this video you'll see data that might contradict your current assumptions.
  - Today were diving into the SERENA-six trial to find out some groundbreaking insights.
  - Lets get started!
  - So, the trial screened over three thousand two hundred fifty-six patients with HR-positive breast cancer, using ctDNA checks every two to three months.
  - But heres the twistabout forty percent developed ESR1 mutations, causing resistance to aromatase inhibitors with CDK four/six inhibitors.
  - Only three hundred fifteen patients switched to camizestrant on time, with others ineligible due to advanced disease.
  - The median progression-free survival?
  - Just nine point two months with aromatase inhibitors, but a whopping sixteen months with camizestrant, cutting progression risk by fifty-six percent.
  - Quality of life dropped after six point four months with the old treatment, but stretched to twenty-three months with camizestrant, with only one point three percent discontinuing.
  - Yet, overall survival data remains unclearimmature at the interim analysis.
  - What a rollercoaster!
  - So, what does this mean?
- Page 1 of 2Baby Oncologists Video Transcript SERENA-6 Trial Insights
- Camizestrant offers a clear edge in delaying progression and improving quality of life, but we need more time for the full survival picture.
  - If youre intrigued, go to [OncologyTube.com](https://OncologyTube.com) to see more videos on the SERENA-six trial and a web companion.
  - Thank you!